RUS 3108 is being developed for the treatment of atherosclerosis, the major cause of cardiovascular disorders such as heart attacks and stroke by Dr. Reddy’s Laboratories. The drug’s Phase I... The drug’s Phase I clinical trials have been initiated in Europe to assess safety of the drug compound in healthy volunteers.
- Mechanism
- Curator reviewed
RUS-3108 represents a new approach to the treatment of atherosclerosis. It is a first-in-class compound and works to directly modulate the disease through affecting multiple pathways involved in the disease process such as inflammation, proliferation and thrombosis by inducing a protein called perlecan. It has the potential to prevent the formation of atherosclerotic plaques and reverse atherosclerosis.
- Primary indication
- Investigated for use/treatment in atherosclerosis.Curator reviewed
- Code names
- RUS 3108
Resolves to
What you can answer from here — as of July 03, 2026
Which drugs share a target with RUS 3108, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account